480
W. Wei et al. / Tetrahedron: Asymmetry 19 (2008) 476–481
(34 mg, 0.1 mmol) was added. After stirring for 10 min,
diphenylzinc (1.95 ml of 0.128 M solution in toluene,
0.25 mmol) was added to the solution. The reaction mix-
ture was warmed to 25 °C and stirred for 1 h, then a CHCl3
(3 ml) solution of nitrone 2a (117 mg, 0.5 mmol) was
added. The resulting solution was stirred at 25 °C for 1 h
and quenched by the addition of a saturated aq NH4Cl
solution. After filtration of the precipitate, the filtrate was
extracted with AcOEt. The combined extracts were washed
with brine, dried over Na2SO4, and condensed under re-
duced pressure. The residue was separated by TLC on
SiO2 to isolate 3a (hexane/AcOEt = 3:1) in 75% yield
(117 mg).
7.14–7.39 (m, 8H), 7.52–7.58 (m, 2H); HRMS (FAB+),
found: m/z 322.21737. Calcd for C22H28NO: (M++H),
322.21709. The enantiomer ratio was determined by HPLC
analysis (Daicel Chiralcel OD-H, hexane/EtOH = 75:1, de-
tected at 254 nm).
4.5.6. Asymmetric phenylation of (Z)-1-phenyl-N-[(E)-3-
phenylallylidene]methanamine oxide 5 (Scheme 3). To a
CH2Cl2 (1.8 ml) solution of (R,R)-DTBT (95 mg,
0.36 mmol) was added dimethylzinc (0.78 ml of 1.0 M solu-
tion in hexane, 0.78 mmol) at 0 °C under an argon
atmosphere, and the mixture was stirred for 10 min. To
the solution, a CH2Cl2 (1.8 ml) solution of racemic
N-benzyl-N-[1-(4-methoxyphenyl)-3-phenylprop-2-ynyl]-
hydroxylamine (21 mg, 0.06 mmol) was added. After stir-
ring for 10 min, diphenylzinc (2.3 ml of 0.129 M solution
in toluene, 0.30 mmol) was added to the solution. Then a
CH2Cl2 (1.8 ml) solution of nitrone 5 (72 mg, 0.30 mmol)
was added. The resulting solution was stirred at 25 °C for
24 h and then quenched by the addition of a saturated aq
NaHCO3 solution. After filtration of the precipitate, the fil-
trate was extracted with AcOEt. The combined extracts
were washed with brine, dried over Na2SO4, and condensed
under reduced pressure. The residue was separated by TLC
on SiO2 to isolate 6 (hexane/AcOEt = 10:1) in 76% yield
(73 mg).
4.5.2. (S)-N-Benzyl-N-(1,3-diphenylprop-2-ynyl)hydroxyl-
25
amine 3a.10 Mp 133–134 °C (from EtOH); ½aꢁD ¼ ꢀ42
(c 1.23, EtOH, 92% ee); IR (KBr) 3239, 3029, 2905, 1597,
1488, 1452, 1331, 1298, 1179, 1070, 1026, 1003, 988, 916,
1
826, 812, 757, 729, 690 cmꢀ1; H NMR (CDCl3): d 3.89
(d, J = 12.69 Hz, 1H, CH2Ph), 3.99 (d, J = 12.69 Hz, 1H,
CH2Ph), 4.87 (s, 1H, ArCHNBn), 5.69 (s, 1H, OH),
7.28–7.37 (m, 10H), 7.59–7.61 (m, 5H). Calcd for
C22H19NO: C, 84.31; H, 6.11; N, 4.47. Found: C, 84.31;
H, 6.15; N, 4.43. The enantiomer ratio was determined
by HPLC analysis (Daicel Chiralcel OD-H, hex-
ane/iPrOH = 45:1, detected at 254 nm).
4.5.3. (S)-N-Benzyl-N-(1-phenyl-3-p-tolylprop-2-ynyl)hydr-
25
4.5.7. (R,E)-N-Benzyl-N-(1,3-diphenylallyl)hydroxylamine
oxylamine 3b. Mp 135–136 °C (from EtOH); ½aꢁD ¼ ꢀ45
25
6. Obtained as an oil, ½aꢁD ¼ þ7 (c 0.73, EtOH, 49%
(c 1.23, EtOH, 87% ee); IR (KBr) 3236, 3028, 2918, 1600,
1542, 1508, 1495, 1453, 1353, 1289, 1075, 1029, 1020,
985, 913, 861, 815, 757, 738, 696 cmꢀ1; 1H NMR (CDCl3):
d 2.37 (s, 3H, CH3), 3.99 (s, 2H, CH2Ph), 4.93 (s, 1H,
ArCHNBn), 5.25 (s, 1H, OH), 6.87–7.86 (m, 14H). Calcd
for C23H21NO: C, 84.37; H, 6.47; N, 4.28. Found: C,
84.09; H, 6.50; N, 4.34. The enantiomer ratio was deter-
mined by HPLC analysis (Daicel Chiralcel OD-H, hex-
ane/iPrOH = 60:1, detected at 254 nm).
ee); IR (neat) 3529, 3082, 3059, 3027, 2923, 2850, 1599,
1494, 1452, 1246, 1072, 1028, 966, 744, 697 cmꢀ1 1H
;
NMR (CDCl3): d 3.81 (d, J = 13.42 Hz, 1H, CH2Ph),
3.95 (d, J = 13.42 Hz, 1H, CH2Ph), 4.44 (d, J = 8.04 Hz,
1H), 4.75 (s, 1H, OH), 6.54 (m, 1H), 6.65 (d,
J = 11.20 Hz, 1H), 7.27–7.58 (m, 15H); HRMS (FAB+),
found: m/z 316.16955. Calcd for C22H22NO: (M++H),
316.17014. The enantiomeric ratio was determined by
HPLC analysis (Daicel Chiralcel OD-H, hex-
ane/iPrOH = 20:1, detected at 254 nm).
4.5.4. (S)-N-Benzyl-N-[3-(4-bromophenyl)-1-phenylprop-2-
ynyl]hydroxylamine 3c. Mp 166–167 °C (from EtOH);
25
½aꢁD ¼ ꢀ69 (c 0.50, EtOH, 90% ee); IR (KBr) 3339, 3063,
Acknowledgments
3030, 2971, 2894, 1602, 1485, 1453, 1393, 1297, 1272,
1070, 1049, 1011, 880, 824, 736, 699 cmꢀ1 1H NMR
;
The present work was financially supported in part by
Grant-in-Aid for Scientific Research on Priority Areas
‘‘Advanced Molecular Transformations of Carbon Re-
sources” from The Ministry of Education, Culture, Sports,
Science and Technology (MEXT) and NOVARTIS Foun-
dation (Japan) for the Promotion of Science.
(CDCl3): d 3.98 (d, J = 13.17 Hz, 1H, CH2Ph), 4.06 (d,
J = 13.17 Hz, 1H, CH2Ph), 4.98 (s, 1H, ArCHNBn), 5.05
(s, 1H, OH), 7.28–7.49 (m, 12H), 7.57–7.63 (m, 2H). Calcd
for C22H18NOBr: C, 67.35; H, 4.60; N, 3.57. Found: C,
67.51; H, 4.70; N, 3.52. The enantiomer ratio was deter-
mined by HPLC analysis (Daicel Chiralcel OD-H, hex-
ane/iPrOH = 45:1, detected at 254 nm).
References
4.5.5. (S)-N-Benzyl-N-(1-phenylnon-2-ynyl)hydroxylamine
25
1. (a) Bloch, R. Chem. Rev. 1998, 98, 1407; (b) Kobayashi, S.;
Ishitani, H. Chem. Rev. 1999, 99, 1069.
3d. Obtained as an oil, ½aꢁD ¼ ꢀ43 (c 1.14, EtOH, 87%
ee); IR (neat) 3256, 3086, 3063, 3030, 2930, 2857, 2227,
1603, 1585, 1558, 1494, 1454, 1330, 1180, 1074, 1050,
879, 831, 813, 755, 735, 699 cmꢀ1;1H NMR (CDCl3): d
0.90 (t, J = 6.69 Hz, 3H, CH3), 1.23–1.35 (m, 4H,
(CH2)2), 1.43–1.51 (m, 2H, CH2), 1.58–1.74 (m, 2H,
CH2), 2.38 (t, J = 5.04 Hz, 2H, C„CCH2), 3.90 (d,
J = 13.11 Hz, 1H, CH2Ph), 4.00 (d, J = 13.11 Hz, 1H,
CH2Ph), 4.77 (s, 1H, ArCHNBn), 4.89 (s, 1H, OH),
2. (a) Kuo, D.; Weidner, J.; Griffin, P.; Shah, S. K.; Knight, W.
B. Biochemistry 1994, 33, 8347; (b) Finke, E. P.; Shah, S. K.;
Fletcher, D. S.; Ashe, B. M.; Brause, K. A.; Chandler, G. O.;
Dellea, P. S.; Hand, K. M.; Maycock, A. L.; Osinga, D. G.;
Underwood, D. J.; Weston, H.; Davies, P.; Doherty, J. B. J.
Med. Chem. 1995, 38, 2449; (c) Grell, W.; Hurnaus, R.; Griss,
G.; Sauter, R.; Rupprecht, E.; Mark, M.; Luger, P.; Nar, H.;
Wittneben, H.; Muller, P. J. Med. Chem. 1998, 41, 5219; (d)
¨